Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Troriluzole

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Biohaven Reports Positive Phase 1 Degrader Data, NDA Submission
    Biohaven Reports Positive Phase 1 Degrader Data, NDA Submission

    16 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biohaven-reports-positive-phase-1-degrader-data-achieving-deep-targeted-igg-reductions-in-the-lowest-subcutaneous-dose-tested-announces-nda-submission-for-troriluzole-in-sca-and-provides-other-key-program-updates-302332472.html

    PR NEWSWIRE
    16 Dec 2024
    Share Share
    Biohaven Achieves Topline Results in Study of Troriluzole in SCA
    Biohaven Achieves Topline Results in Study of Troriluzole in SCA

    24 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biohaven-achieves-positive-topline-results-in-pivotal-study-of-troriluzole-in-spinocerebellar-ataxia-sca-302255056.html

    PR NEWSWIRE
    24 Sep 2024
    Share Share
    Biohaven To Discuss Topline Results in Spinocerebellar Ataxia
    Biohaven To Discuss Topline Results in Spinocerebellar Ataxia

    20 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biohaven-announces-conference-call-to-discuss-topline-pivotal-study-results-in-spinocerebellar-ataxia-302254638.html

    PR NEWSWIRE
    20 Sep 2024
    Share Share
    A blow for Biohaven as FDA refuses failed rare disease drug
    A blow for Biohaven as FDA refuses failed rare disease drug

    27 Jul 2023

    // James Waldron FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/further-blow-biohaven-fda-refuses-consider-failed-rare-disease-drug-approval

    James Waldron FIERCE BIOTECH
    27 Jul 2023
    Share Share
    Biohaven adds to a long list of Alzheimer's drug failures
    Biohaven adds to a long list of Alzheimer's drug failures

    20 Jan 2021

    // Jacob Bell BIOPHARMADIVE

    https://www.biopharmadive.com/news/biohaven-adds-to-a-long-list-of-alzheimers-drug-failures/593578/

    Jacob Bell BIOPHARMADIVE
    20 Jan 2021
    Share Share
    MediciNova Receives Notice of Allowance for New Patent MN-166 (ibudilast)
    MediciNova Receives Notice of Allowance for New Patent MN-166 (ibudilast)

    19 Jan 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/01/18/2160200/0/en/MediciNova-Receives-Notice-of-Allowance-for-New-Patent-Covering-the-Combination-of-MN-166-ibudilast-and-Riluzole-for-the-Treatment-of-Amyotrophic-Lateral-Sclerosis-ALS-in-Japan.html

    GLOBENEWSWIRE
    19 Jan 2021
    Share Share